This bill prohibits the Department of Health and Human Services from finalizing, implementing, or enforcing the proposed "Safe and Appropriate Foster Care Placement Requirements for Titles IV-E and IV-B" rule (published September 28, 2023). It directly affects federal foster care programs by blocking a specific rule that would have required states to consider religious beliefs when placing children in foster care. The key mechanism is a clear statutory ban on the rule's implementation, preventing it from taking effect. The bill does not create new requirements but stops the enforcement of this particular federal regulation.
The Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.
This bill establishes an Agricultural Trade Enforcement Task Force to address foreign trade barriers harming U.S. agricultural exports, specifically targeting India's WTO-violating price support programs for rice, wheat, and other commodities. The Task Force, led by the U.S. Trade Representative and Agriculture Department, must identify systemic trade barriers, develop enforcement strategies, and file a WTO dispute against India within 60 days of consultations if needed. It requires quarterly reports to Congress on progress, including a specific plan to challenge India's subsidies that exceed WTO limits (e.g., rice supports at 93.9% of production value). The bill directly affects U.S. farmers, ranchers, and exporters who face market access barriers due to these foreign subsidies.
HR 5737, the Elevating HSA Limits Act of 2023, increases the maximum annual contribution limits for Health Savings Accounts (HSAs) to match the deductible and out-of-pocket limits of qualifying high-deductible health insurance plans. This change directly affects individuals with HDHPs who use HSAs, as their annual contribution caps will now automatically adjust each year based on the current plan's deductible and out-of-pocket maximums instead of fixed 2023 dollar amounts. The bill amends the Internal Revenue Code to replace the current fixed limits ($2,250 for self-only coverage and $4,500 for family coverage) with a dynamic formula tied to plan costs. These changes apply to tax years beginning after December 31, 2023.
This bill amends tax code rules to allow married individuals to contribute to their own health flexible spending account (FSA) even if their spouse already has an FSA. It permits these contributions provided the combined reimbursements for both spouses do not exceed the total eligible expenses that would apply if the spouse's account didn't exist. The change applies to health savings plans starting in 2024, affecting married taxpayers with dual FSA coverage. It clarifies the reimbursement limits without creating new benefits or altering existing FSA structures.
The ORPHAN Cures Act amends the Drug Price Negotiation Program under the Social Security Act to clarify how orphan drugs (medications for rare diseases affecting fewer than 200,000 people in the U.S.) are treated. It ensures that periods when a drug was designated as an orphan drug are excluded from the time calculation used to determine when the drug can no longer be excluded from price negotiations. The bill also updates the definition to allow a single drug to be designated for multiple rare diseases, rather than just one. This change provides clearer rules for manufacturers and the government regarding orphan drug exclusions in the program.
The Maintaining Investments in New Innovation Act (HR 5547) extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines an "advanced drug product" as a drug using genetically targeted technology to change how genes work, such as drugs that suppress or activate gene function. The bill amends the Social Security Act to update the definition of "qualifying single source drug" to include these advanced therapies with the longer exclusivity period. This change directly affects drug manufacturers developing such advanced therapies and influences Medicare's drug coverage rules by delaying generic competition for these specific treatments.
This bill imposes U.S. sanctions on foreign individuals and entities that facilitate North Korea's transfer of arms or material support to Russia for use in Russia's invasion of Ukraine. It targets those responsible for such transfers, including foreign financial institutions enabling significant transactions related to these activities, requiring property blocks and visa restrictions. The bill also amends existing North Korea sanctions to explicitly require halting such material support and mandates the President to submit regular reports to Congress on North Korea's involvement and U.S. strategies to counter it.
This bill clarifies that Medicare must cover external infusion pumps and associated non-self-administrable drugs as durable medical equipment (DME) when specific criteria are met. It directly affects Medicare beneficiaries requiring home infusion therapy for drugs that must be prepared just before use, administered by a healthcare professional, or labeled for external pump use at least monthly. Key provisions require the drug's FDA labeling to specify external pump administration, safe home delivery by qualified suppliers, and preparation/administration requirements. The bill mandates Medicare coverage under existing rules (LCD L33794) for qualifying treatments, effective upon enactment or FDA approval, whichever is later.
This bill allows employees to directly transfer funds from a health flexible spending account (FSA) or health reimbursement arrangement (HRA) to a health savings account (HSA) when switching to a high-deductible health plan after a gap in coverage. It sets a dollar limit on these transfers based on annual HSA contribution rules and requires the transfer to occur after a significant period without coverage. Employers must report these transfers on employees' W-2 forms. The changes apply to distributions made after December 31, 2023.
HR 5107, the Pandemic Unemployment Fraud Recoupment Act, extends the statute of limitations for enforcing fraud related to pandemic unemployment benefits from 3 years to 10 years across multiple programs, including Pandemic Unemployment Assistance, Federal Pandemic Unemployment Compensation, and Lost Wages Assistance. It requires states to recover overpayments from individuals who knowingly received benefits they weren’t entitled to, through deductions from future unemployment benefits, while maintaining existing due process protections like hearings before repayment. States may waive repayment if the overpayment wasn’t the individual’s fault or if repayment would be unfair. The bill applies directly to individuals who received pandemic-era unemployment benefits through fraudulent means, ensuring states have a longer timeframe to address these cases under established fraud procedures.
This bill amends the Affordable Care Act and Medicaid/CHIP programs to deny health insurance subsidies, coverage, and related benefits to individuals with Deferred Action for Childhood Arrivals (DACA) status. Specifically, it excludes people lawfully present only due to the 2012 DHS memo granting deferred action from eligibility for ACA subsidies, Medicaid, and the State Children's Health Insurance Program (CHIP). The bill requires states to remove DACA recipients from enrollment in health plans and rescind any existing waivers that allowed such coverage. It directly affects approximately 800,000 DACA recipients who currently qualify for ACA subsidies and Medicaid/CHIP under existing rules.
